TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) Investor Filed Lawsuit Against Acquisition By Allergan plc

  • If you purchased shares of Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) and currently hold any of those NASDAQ:KYTH shares, you have certain options and you should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Lawsuit Overview

Company
Kythera Biopharmaceuticals Inc
Security
NASDAQ: KYTH

Case Name
Kythera Biopharmaceuticals Deal Case 06/29/2015
Type of Lawsuit
Mergers and Acquisition
You must register or login to receive notifications.

Click here to subscribe to Kythera Biopharmaceuticals Inc.
Summary

June 30, 2015 (Shareholders Foundation) - An investor who currently holds shares of Kythera Biopharmaceuticals Inc (NASDAQ:KYTH), filed a lawsuit in effort to halt the proposed takeover of Kythera Biopharmaceuticals Inc by Allergan plc for a value of $75 per share is unfair to NASDAQ:KYTH stockholders.
The plaintiff alleges that the defendants breached their fiduciary duties owed to NASDAQ:KYTH stockholders by agreeing to sell Kythera Biopharmaceuticals Inc. too cheaply via an unfair process to Allergan plc.

On June 17, 2015, Allergan plc (NYSE:AGN) and KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) announced that they have entered into an agreement under which Allergan has agreed to acquire Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) in a cash and equity transaction valued at $75 per KYTHERA share, or approximately $2.1 billion, subject to the fulfillment of certain customary conditions summarized below.

However, the plaintiff claims that the proposed consideration NASDAQ:KYTH shareholders will receive is grossly inadequate and undervalues Kythera Biopharmaceuticals Inc. Indeed, at least one analyst has set the high target price for NASDAQ: KYTH shares at $85.00 per share. . In addition, the plaintiff claims that the process is also unfair to NASDAQ:KYTH stockholders.